{"id":"NCT00404820","sponsor":"Novartis","briefTitle":"Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis","officialTitle":"A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2006-11-29","resultsPosted":"2011-07-01","lastUpdate":"2011-07-01"},"enrollment":604,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Zoledronic acid 5 mg solution","otherNames":[]},{"type":"DRUG","name":"Alendronate 70 mg tablets","otherNames":[]},{"type":"DRUG","name":"Calcium/Vitamin D","otherNames":[]}],"arms":[{"label":"Zoledronic acid 5 mg","type":"EXPERIMENTAL"},{"label":"Alendronate 70 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.","primaryOutcome":{"measure":"Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat Population","timeFrame":"Screening to end of study (Month 12)","effectByArm":[{"arm":"Zoledronic Acid 5 mg","deltaMin":0.282,"sd":0.195},{"arm":"Alendronate 70 mg","deltaMin":0.27,"sd":0.266}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":408},"commonTop":["Influenza like illness","Arthralgia","Back pain","Headache","Nasopharyngitis"]}}